低甲基化药物联合维奈克拉是复发/难治性早期前T细胞急性淋巴细胞白血病的有效挽救治疗
本文报告5例复发/难治性早期前T细胞急性淋巴细胞白血病(ETP-ALL)成人患者,接受低甲基化药物联合维奈克拉(HMA-VEN)治疗,显示该方案有效,且能使缓解者桥接至以治愈为目的的异基因造血干细胞移植。
要点
- ETP-ALL缺乏有效挽救方案,HMA-VEN在5例R/R ETP-ALL成人中显示疗效。
- HMA-VEN可使治疗有反应者桥接至以治愈为目的的异基因造血干细胞移植。
- 靶向BCL-2家族蛋白(如维奈克拉)在ETP-ALL中具有治疗活性。
核心结论
- HMA-VEN是复发/难治性ETP-ALL的有效挽救治疗,并可使缓解者桥接至以治愈为目的的异基因造血干细胞移植。
研究设计与样本
- 病例系列,纳入5例接受HMA-VEN治疗的复发/难治性ETP-ALL成人患者。
主要发现
- 5例复发/难治性ETP-ALL成人患者接受HMA-VEN治疗,该治疗有效,且使治疗有反应者桥接至以治愈为目的的异基因造血干细胞移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL) is a distinct biological subtype of T-ALL and is associated with poor clinical outcomes due to the lack of effective salvage regimens that can induce remission and bridge patients to allogeneic stem cell transplantation. Targeting antiapoptotic BCL-2 family proteins has demonstrated therapeutic efficacy in ETP-ALL with agents such as venetoclax. We present a case series of five adult patients with relapsed or refractory (R/R) ETP-ALL who were treated with a hypomethylating agent (HMA) in combination with venetoclax (HMA-VEN) and demonstrate that this therapy is efficacious and can bridge responders to allogeneic stem cell transplantation with curative intent.
引用
- Agrawal V, Arslan S, Pourhassan H, et al. Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T-cell precursor acute lymphoblastic leukaemia. Br J Haematol. 2025. PMID: 40205647. doi:10.1111/bjh.20065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。